Literature DB >> 10086328

No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins.

T Tateishi1, M Watanabe, H Moriya, S Yamaguchi, T Sato, S Kobayashi.   

Abstract

Ethnic differences in the pharmacokinetics of nifedipine, a substrate of CYP3A, and in CYP3A7 expression have been reported. The aim of the present study was to measure the protein levels of CYP3A4, CYP3A5, and CYP3A7 and nifedipine oxidation activity in hepatic microsomes from 15 Caucasian and 15 Japanese patients for comparison between the two ethnic groups. Nifedipine oxidation activity and CYP3A4 protein level were well correlated. No significant difference between Caucasian and Japanese microsomal samples was found in nifedipine oxidation activity or in the CYP3A4 protein level. CYP3A5 was detected in 6 of 15 Caucasian samples and in 5 of 15 Japanese samples, but no ethnic difference was found in either the frequency of expression or its protein level. CYP3A7 was found in 10 of 15 Caucasian samples and in 14 of 15 Japanese samples. Although the estimated CYP3A7 protein level was higher in the Japanese than in the Caucasian samples, its protein level was much lower than that of CYP3A4. These results imply that the contribution of CYP3A5 or CYP3A7 to the purported Caucasian-Japanese ethnic difference in the overall CYP3A activity seems to be small.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10086328     DOI: 10.1016/s0006-2952(98)00375-x

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  12 in total

Review 1.  Cytochrome P450 3A and their regulation.

Authors:  Oliver Burk; Leszek Wojnowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-21       Impact factor: 3.000

2.  CYP3A phenotypes and genotypes in North Indians.

Authors:  Naushad Rais; Yogesh K Chawla; Krishan K Kohli
Journal:  Eur J Clin Pharmacol       Date:  2006-04-21       Impact factor: 2.953

Review 3.  Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.

Authors:  Ron H N van Schaik
Journal:  Invest New Drugs       Date:  2005-12       Impact factor: 3.850

Review 4.  Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism.

Authors:  Bertrand Rochat
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 5.  Cytochrome P450 3A: ontogeny and drug disposition.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

6.  Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients.

Authors:  Masatomo Miura; Kazuyuki Inoue; Shigeru Satoh; Yoshihiko Itoh; Hideaki Kagaya; Hitoshi Tada; Yorihisa Tanaka; Tomonori Habuchi; Toshio Suzuki
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

Review 7.  Pharmacokinetic considerations relating to tacrolimus dosing in the elderly.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 8.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

9.  Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese.

Authors:  Ichiro Fukazawa; Naoki Uchida; Eiji Uchida; Hajime Yasuhara
Journal:  Br J Clin Pharmacol       Date:  2004-04       Impact factor: 4.335

10.  Bufalin inhibits CYP3A4 activity in vitro and in vivo.

Authors:  Hai-yun Li; Wen Xu; Xi Zhang; Wei-dong Zhang; Li-wei Hu
Journal:  Acta Pharmacol Sin       Date:  2009-05       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.